U.S. Markets closed

Bayer Aktiengesellschaft (BAYN.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
55.97+0.04 (+0.07%)
At close: 5:35PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close55.93
Open56.00
Bid55.93 x 28400
Ask55.94 x 2100
Day's Range55.06 - 56.06
52 Week Range44.85 - 78.34
Volume2,758,782
Avg. Volume3,851,506
Market Cap54.986B
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-5.72
Earnings DateNov 03, 2020
Forward Dividend & Yield2.80 (5.01%)
Ex-Dividend DateApr 29, 2020
1y Target Est119.69
  • Moody's

    Regeneron Pharmaceuticals, Inc. -- Moody's assigns Baa3 issuer rating to Regeneron

    NOTE: On August 07, 2020, the press release was corrected as follows: In the debt list, the description under “Ratings assigned” was changed to “Issuer rating, Baa3.” Revised release follows. New York, August 05, 2020 -- Moody's Investors Service ("Moody's") assigned a Baa3 issuer rating to Regeneron Pharmaceuticals, Inc. ("Regeneron"). "Regeneron's investment grade rating reflects growing global scale, strong scientific expertise, and an extremely conservative balance sheet, with very low financial leverage helping to mitigate business risks," stated Michael Levesque, Senior Vice President.

  • Moody's

    Root Bidco S.a.r.l. -- Moody's assigns B2 to Root Bidco, TLB, RCF; negative outlook

    Moody's Investors Service, ("Moody's") today assigned a B2 corporate family rating (CFR) and a B2-PD probability of default rating to Root Bidco S.a.r.l. Moody's expects to withdraw all ratings for EUROPEAN CROPS PRODUCTS 2 S.A.R.L. once the transaction closes in late 2020. The company since 2016 has grown from a revenue base of E225 million organically and through acquisitions.

  • Moody's

    Regeneron Pharmaceuticals, Inc. -- Moody's rates Regeneron's sr. notes Baa3; stable outlook

    Moody's Investors Service ("Moody's") assigned a Baa3 rating to the new senior unsecured notes of Regeneron Pharmaceuticals, Inc. ("Regeneron"). "Regeneron's investment grade rating reflects growing global scale, strong scientific expertise, and an extremely conservative balance sheet, with very low financial leverage helping to mitigate business risks," stated Michael Levesque, Senior Vice President.